Why did Novartis keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. We went all Novartis this week, explaining the shocking news that the Swiss pharma giant submitted falsified data to the FDA and then waited three months to inform regulators. We discuss what we know, what remains unanswered, the implications for Novartis’s corporate rebrand, and why this was awkward timing for Vas Narasimhan, the company’s ascendant CEO.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nothing to see here folks, it won’t change anything. We are seeing these huge corporate criminals get away with this kind of thing time and again. The FDA has been strategically underfunded for years and no longer capable of enforcing laws or regulations. It is really clear the only objective is profit and covering for corporate crimes. What will be interesting is how this corporation will get a nice write up in formerly credible appearing publications.

Your daily dose of news in health and medicine

Privacy Policy